[ESMO 2019] Efficacy of PD-1 Inhibitors Confirmed in the Treatment of “MSI” Tumours

The pooled analysis of two studies, KEYNOTE-164 and KEYNOTE-168, in which Pr Thierry André, Head of the Digestive Oncology Department at the Saint-Antoine AP-HP Hospital, participated, confirms the exceptional efficacy of pembrolizumab (anti-PD1 antibodies) in the treatment of unstable micro satellite cancers (MSI), rare colorectal cancers that occur either in a hereditary context of Lynch syndrome or spontaneously without any particular environment with an incidence that increases with age. This particular form, characterized by abnormalities in DNA repair, promotes the formation and development of cancer cells. To date, MSI status is the best predictor of response to PD-1 inhibitors. These data will be presented orally at the ESMO congress on Monday, September 30, 2019. 

More information : https://www.aphp.fr/contenu/esmo-2019-lefficacite-des-inhibiteurs-de-pd-1-confirmee-dans-le-traitement-des-tumeurs-msi


Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase 2 KEYNOTE-164 and KEYNOTE-158 studies. 1174O – Lecture time: 10:15 – 10:30

L. Diaz, D. Le, M. Maio, P. Ascierto, R. Geva, D. Motola-Kuba, T. André, E. Van Cutsem, M. Gottfried, E. Elez, J.-P. Delord, D. Jäger, T.W. Kim, R. Guimbaud, T. Yoshino, M. Chen, K. Norwood, P. Marinello, A. Marabelle.